DR. RONALD L RABIN, MD
Medical Practice in Kensington, MD
License number
Maryland D45652
Category
Medical Practice
Type
Pediatric Allergy/Immunology
Address
Address
2
10810 Coinnecticut Ave, Kensington, MD 20895
2101 EAST Jefferson Street Ppqa Medicare Compliance Unit 6 WEST KAISER PERMANENTE, Rockville, MD 20852
2101 EAST Jefferson Street Ppqa Medicare Compliance Unit 6 WEST KAISER PERMANENTE, Rockville, MD 20852
Phone
(301) 929-7100
(301) 929-7114 (Fax)
(301) 816-6660
(301) 816-6308 (Fax)
(301) 929-7114 (Fax)
(301) 816-6660
(301) 816-6308 (Fax)
Professional information
Dr. Ronald L Rabin, Kensington MD - MD (Doctor of Medicine)
Specialties:
Pediatrics, Allergy & Immunology
Address:
10810 Connecticut Ave, Kensington 20895
(301) 929-7100 (Phone), (301) 929-7114 (Fax)
(301) 929-7100 (Phone), (301) 929-7114 (Fax)
Certifications:
Allergy & Immunology, 2007, Pediatrics, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of South Florida / College of Medicine
Graduated: 1979
University of South Florida / College of Medicine
Graduated: 1979
Ronald Louis Rabin, Kensington MD
Specialties:
Pediatrician
Address:
10810 Connecticut Ave, Kensington, MD 20895
Education:
University of South Florida, College of Medicine - Doctor of Medicine
Board certifications:
American Board of Allergy and Immunology Certification in Allergy and Immunology, American Board of Pediatrics Certification in Pediatrics
Compositions For Detecting Human Interferon-Alpha Subtypes And Methods Of Use
US Patent:
2011031, Dec 22, 2011
Filed:
Nov 20, 2009
Appl. No.:
13/130346
Inventors:
Ronald Rabin - Rockville MD, US
Viraj Pramod Mane - Rockville MD, US
Viraj Pramod Mane - Rockville MD, US
Assignee:
USA, as Represented by the Secretary, Department of Health & Human Services (The Government) - Bethesda MD
International Classification:
C12Q 1/68, C07H 1/00
US Classification:
435 611, 435 612, 536 253
Abstract:
The invention provides highly sensitive, specific and efficient quantitative real-time PCR compositions, methods and assay kits to detect at least one IFN subtype and/or IFN subtype allotypic variants. Primer/probe sets complementary to the coding sequence of an IFN subtype of interest avoid spurious detection of degraded mRNA and enhances the correlation between the IFN subtype that is measured by the assays of the invention and the protein that is actually expressed. The invention also provides methods for designing primers and methods of using the compositions and assay kits. The compositions, kits, and methods of the invention may be used, for example, to monitor vaccine efficacy, autoimmune disease, chronic infections, or tumor therapy.
Rapid Assay For Infection In Neonates
US Patent:
6077665, Jun 20, 2000
Filed:
Apr 8, 1997
Appl. No.:
8/833677
Inventors:
Erica E. Weirich - Redwood City CA
Ronald L. Rabin - Rockville MD
Yvonne Maldonado - Redwood City CA
William E. Benitz - Palo Alto CA
Leonore A. Herzenberg - Stanford CA
Leonard A. Herzenberg - Stanford CA
Ronald L. Rabin - Rockville MD
Yvonne Maldonado - Redwood City CA
William E. Benitz - Palo Alto CA
Leonore A. Herzenberg - Stanford CA
Leonard A. Herzenberg - Stanford CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C12Q 168, G01N 3353
US Classification:
435 6
Abstract:
A rapid assay for infection in immunodeficient patients such as neonates or immunocompromised patients (e. g. HIV or transplant patients) allows diagnosis at initial evaluation, such that antibiotic treatment and confinement to an intensive care unit can be avoided for uninfected patients. The assay can be used for detecting bacterial, viral, or fungal colonization of the blood stream, cerebrospinal fluid (CSF), or urinary tract. The method is particularly useful for sepsis diagnosis. Polymorphonuclear leukocyte (PMN, neutrophil) CD11b (Mac-1, CR3) levels are measured by flow cytometry or laser scanning microscopy in low volume (0. 1 ml) whole blood samples. A dual-laser FACS identifies neutrophils by FITC-conjugated anti-CD15 fluorescent antibodies, and identifies surface neutrophil CD11b marked with PE-conjugated anti-CD11b antibodies. Spontaneous upregulation of CD11b is prevented by handling samples at 4. degree. C. or adding a stabilizing compound such as anti-CD14 antibody or adenosine to the samples.
Methods For Determining T-Cell Profiles Of Immunocompromised Subjects
US Patent:
5968755, Oct 19, 1999
Filed:
Sep 26, 1996
Appl. No.:
8/721260
Inventors:
Mario Roederer - Redwood City CA
Ronald Rabin - Rockville MD
Leonard A. Herzenberg - Stanford CA
Leonore A. Herzenberg - Stanford CA
Ronald Rabin - Rockville MD
Leonard A. Herzenberg - Stanford CA
Leonore A. Herzenberg - Stanford CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
G01N 3353
US Classification:
435 724
Abstract:
A method of identifying an abnormal T-cell profile of an immunocompromised subject is disclosed. The method involves detecting the immunoreactivity of T-cells with at least two antibodies selectively reactive with naive T-cell surface proteins and comparing data from cells isolated from an immunocompromised subject with data from cells isolated form a non-immunocompromised subject. Also disclosed are methods of screening drugs or compounds for efficacy to stimulate the production of naive T cells in a subject.